These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20969973)

  • 21. Integrative oncoproteomics strategies for anticancer drug discovery.
    Liu R; Wang K; Yuan K; Wei Y; Huang C
    Expert Rev Proteomics; 2010 Jun; 7(3):411-29. PubMed ID: 20536311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer.
    Chapal N; Molina L; Molina F; Laplanche M; Pau B; Petit P
    Fundam Clin Pharmacol; 2004 Aug; 18(4):413-22. PubMed ID: 15312147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine.
    Zineh I; Huang SM
    Biomark Med; 2011 Dec; 5(6):705-13. PubMed ID: 22103607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly.
    Erlanson DA; Hansen SK
    Curr Opin Chem Biol; 2004 Aug; 8(4):399-406. PubMed ID: 15288250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted proteomics by selected reaction monitoring mass spectrometry: applications to systems biology and biomarker discovery.
    Elschenbroich S; Kislinger T
    Mol Biosyst; 2011 Feb; 7(2):292-303. PubMed ID: 20976349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mathematical biodescriptors of proteomics maps: background and applications.
    Basak SC; Gute BD
    Curr Opin Drug Discov Devel; 2008 May; 11(3):320-6. PubMed ID: 18428085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Industrialized MS-based proteomics in the search for circulating biomarkers.
    Migneault I; Hunter JM
    Bioanalysis; 2009 Sep; 1(6):1149-63. PubMed ID: 21083081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenomics/pharmacoproteomics Europe.
    Meister W
    Pharmacogenomics; 2002 Jul; 3(4):449-52. PubMed ID: 12164769
    [No Abstract]   [Full Text] [Related]  

  • 31. Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays.
    Wulfkuhle JD; Edmiston KH; Liotta LA; Petricoin EF
    Nat Clin Pract Oncol; 2006 May; 3(5):256-68. PubMed ID: 16683004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based approaches to antibiotic drug discovery.
    Nicola G; Abagyan R
    Curr Protoc Microbiol; 2009 Feb; Chapter 17():Unit17.2. PubMed ID: 19235149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
    Lesko LJ; Woodcock J
    Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biomarkers: "Found in translation"].
    Lockhart BP; Walther B
    Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview of molecular, cellular, and genetic neurotoxicology.
    Wallace DR
    Neurol Clin; 2005 May; 23(2):307-20. PubMed ID: 15757786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical points in urinary proteomics.
    Thongboonkerd V
    J Proteome Res; 2007 Oct; 6(10):3881-90. PubMed ID: 17824635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ethical and legal implications of pharmacogenomics.
    Rothstein MA; Epps PG
    Nat Rev Genet; 2001 Mar; 2(3):228-31. PubMed ID: 11256075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic methods for drug target discovery.
    Sleno L; Emili A
    Curr Opin Chem Biol; 2008 Feb; 12(1):46-54. PubMed ID: 18282485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomics technology and therapeutics.
    Hong ML; Jiang N; Gopinath S; Chew FT
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):563-8. PubMed ID: 16700895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary proteomics: towards biomarker discovery, diagnostics and prognostics.
    Thongboonkerd V
    Mol Biosyst; 2008 Aug; 4(8):810-5. PubMed ID: 18633482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.